Full-Time

Senior Principal Scientist

Computational Chemist

Posted on 3/31/2026

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

No salary listed

Maidstone, UK + 1 more

More locations: Cambridge, UK

In Person

Category
Biology & Biotech (2)
,
Required Skills
Machine Learning
Medicinal Chemistry
Biochemical Assays
Requirements
  • MSc/PhD in a relevant scientific discipline (Pharmaceutical Sciences, Chemistry, Computational Chemistry) with a solid foundation in molecular modelling built in a pharma/biotech/CRO setting.
  • Expert knowledge in Computer-Aided Drug Design software packages and modern molecular modelling techniques.
  • Sound knowledge in cutting-edge cheminformatic tools, AI/ML-enabled technologies, and in silico drug design, including both structure- and ligand-based methodologies.
  • Passion for drug discovery with a deep entrepreneurial and problem-solving attitude.
  • Mastery of all the theoretical and practical principles of medicinal chemistry and drug design.
  • Broad knowledge of biophysical, biochemical, and cell-based assays used in the early stages of the drug discovery process.
  • In depth understanding of multi-parameter optimization and ability to integrate disease biology, ADME/DMPK and toxicology data to solve complex drug discovery problems.
  • Excellent leadership, management, organizational and team-working skills, and a talent to deliver project milestones within the expected time frame.
  • Demonstrated track record of scientific publications.
  • Exceptional oral, written, and interpersonal communication skills, and ability to develop and grow strong cross-functional collaborations.
Responsibilities
  • Utilize modern molecular modelling methods to support different stages of R&D programs.
  • Collaborate effectively with other departments and functions to advance research discovery projects expeditiously from hit identification to high quality preclinical candidates.
  • Design, lead and drive computational studies on projects throughout the several discovery phases and ensure execution on agreed deliverables.
  • Opportunities to lead or co-lead projects in addition to drive discipline-specific endeavours.
  • Set the vision and strategy for computational chemistry.
  • Foster innovative thinking in all areas of departmental activities, with a particular focus on computational and medicinal chemistry.
  • Manage CRO compchem activities, providing expertise and guidance.
  • Present plans and results internally, including at board level, and externally at conferences.
  • Contribute to the writing of patent applications, scientific publications, and internal reports.
  • Develop and mentor less experienced staff.
  • Keep up to date with the latest scientific advances and trends in drug discovery to deliver the next-generation therapies.
  • Undertake ongoing professional development by attending relevant training and conferences.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • Xywav and Epidiolex continue driving double-digit neuroscience revenue growth.
  • Zepzelca's first-line SCLC uptake expands Jazz's oncology franchise rapidly.
  • Chimerix adds dordaviprone, strengthening the late-stage rare-brain-cancer pipeline.

What critics are saying

  • Oxybate franchise concentration exposes revenue to payer pressure and competitive switching.
  • Epidiolex growth slows if adult and long-term-care adoption disappoints.
  • Oncology upside depends on continued Zepzelca and zanidatamab execution.

What makes Jazz Pharmaceuticals unique

  • Rare-disease focus spans neuroscience and oncology with limited-treatment options.
  • Jazz built growth through acquisitions like GW Pharmaceuticals, Celator, and Chimerix.
  • Dublin incorporation and global footprint support cross-border operations and tax optimization.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Jazz Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.

INACTIVE